This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.
Amylin analogues act on a different satiety circuit — area postrema and dorsal raphe — rather than the arcuate pathway GLP-1 agonists use. Because the mechanisms are complementary rather than additive on the same receptor, the combination gets more effect without the tolerability cost of simply pushing GLP-1 higher. REDEFINE-2 put cagrisema near 22.7% against about 15.8% for semaglutide alone.
Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.
What would genuinely help is knowing whether the amylin component adds anything beyond what a higher GLP-1 dose would achieve. I have searched first, so if this is covered somewhere point me at it and I will read it.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
TrialNerd_Beth said:Amylin analogues act on a different satiety circuit — area postrema and dorsal raphe — rather than the arcuate pathway GLP-1 agonists use.
Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.
TrialNerd_Beth said:Amylin analogues act on a different satiety circuit — area postrema and dorsal raphe — rather than the arcuate pathway GLP-1 agonists use.
Pushing back on TrialNerd_Beth here. Two drugs, two side-effect profiles, one price. The efficiency argument only works if the tolerability really is better than dose-escalating a single agent, and I have not seen that demonstrated head to head.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsShort answer first, then the reasoning. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.
LipidDoc_ATL said:Agreed, and one caution: a single measurement is not a measurement.
Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.